Ramona Stelmach,Patrizia Giannatempo,Nicola Nicolai et al.
Ramona Stelmach et al.
Background: Penile cancer is a rare, aggressive malignancy, with incidence varying geographically. The primary risk factor is HPV infection. Squamous cell carcinoma represents the most common histological subtype, account...
Real-World Genomic Landscape of Gastrointestinal Cancers in Asia and the Middle East Using Comprehensive Circulating Tumor DNA Next-Generation Sequencing [0.03%]
基于全面的循环肿瘤DNA下一代测序技术在亚洲和中东胃肠癌症中的真实世界全景研究
Manabu Muto,Yu Sunakawa,Nippun Sandhir et al.
Manabu Muto et al.
Introduction: Gastrointestinal malignancies account for 25% of all cancer cases and 35% of cancer-related mortality. Next-generation sequencing (NGS) can elucidate the genomic landscape of gastrointestinal cancers; tissue...
Prognosis and Therapy of Ovarian Cancer, Part 2: the shifting landscape of medical treatment in ovarian cancer [0.03%]
卵巢癌的预后和治疗（第二部分）：卵巢癌系统性治疗格局的变化
Sara Tato Varela,Alaa El Housheimi,Walther Christian Kuhn
Sara Tato Varela
Background: Ovarian cancer (OC) remains the most common cause of death among all gynecological cancer. For early-stage disease (FIGO stages I and II), staging surgery followed by chemotherapy (CT) with Carboplatin ± Pacl...
Mahdi Yassine,Gerald Illerhaus,Dennis Hahn
Mahdi Yassine
Attending the 2024 ESMO Congress as a young physician is an invaluable opportunity to establish the foundation for a successful and impactful career in oncology. This experience can be transformative for one's professional development. The ...
Sustained clinical response to Olaparib in a patient with metastatic pancreatic cancer and somatic ATM-Mutation R2034Ter: a case report [0.03%]
奥拉帕利治疗携带体细胞ATM突变R2034Ter的转移性胰腺癌患者产生持续临床疗效：1例报告
Marlies Vornhülz,Marianne Angelberger,Simon Sirtl et al.
Marlies Vornhülz et al.
Background Pancreatic cancer remains a lethal disease with limited therapeutic options. The field of targeted therapies is still growing. Treatment with PARP inhibitors has been successfully described mainly in patients with germline mutati...
Case Reports
Oncology research and treatment. 2025 Apr 24:1-12. DOI:10.1159/000545975 2025
Liquid Biopsy in Metastatic Breast Cancer: Path to Personalized Medicine [0.03%]
循环肿瘤DNA在转移性乳腺癌的精准医疗中的作用和挑战
Jan-Philipp Cieslik,Bianca Behrens,Maggie Banys-Paluchowski et al.
Jan-Philipp Cieslik et al.
Background: The detection of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in breast cancer has seen significant progress over the last two decades. These blood-based biomarkers offer a minimally invasi...
Living donor liver transplantation for neo-adjuvant treated, unresectable intrahepatic cholangiocarcinoma (LIVINCA): study protocol for a one-armed, mono-centric, non-randomized trial [0.03%]
新辅助治疗后肝内胆管癌无法切除患者的活体供肝移植（LIVINCA）：单一臂非随机化单中心试验的实验方案
Laura Schwenk,Felix Dondorf,Oliver Rohland et al.
Laura Schwenk et al.
Background Intrahepatic cholangiocarcinoma has demonstrated a consistently increasing incidence in recent years. In cases of unresectability, palliative chemotherapy often remains the only option, typically associated with a poor prognosis....
Prognosis and Therapy of Ovarian Cancer, Part 1: Patient selection and surgical management in advanced ovarian cancer: what tools do we have to make the right decision? [0.03%]
卵巢癌的预后和治疗（一）：晚期卵巢癌患者的甄选及手术治疗——我们有哪些工具能作出正确的决策？
Alaa El Housheimi,Sara Tato Varela,Walther C Kuhn
Alaa El Housheimi
Background: Ovarian cancer is the gynecological cancer with the worst overall survival worldwide. Around 70% of patients are diagnosed in an advanced stage. Since low residual tumor after surgery has been repeatedly obser...
The effect of PET CT parameters on pathological response in patients with HER-2 positive breast cancer receiving neoadjuvant treatment [0.03%]
HER2阳性乳腺癌新辅助治疗患者PET/CT参数对病理反应的影响
Serhat Sekmek,Ozkan Bayrakcı,Mehmet Akif Karacan et al.
Serhat Sekmek et al.
Aim: We aimed to evaluate the relationship between positron emission tomography (PET)/ computed tomography (CT) parameters with pathological complete response (pCR) in patients with HER-2 positive breast cancer who receiv...
Geriatric Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024 [0.03%]
2024年欧洲医学肿瘤学会年会老年肿瘤学亮点
Clemens Wolf,Ulrich Wedding
Clemens Wolf
From 13th to 17th of September 2024, the annual meeting of the European Society for Medical Oncology (ESMO) took place in Barcelona. The ESMO Congress provided a valuable opportunity to learn about new therapeutic approaches, current study ...